What specifically changed in the LVZPF analyst rating?

Goldman Sachs downgraded LVZPF to **Sell** on **February 05, 2026** at 11:14 AM. The note replaced a prior Neutral stance and did not publish a new price target.

Did the downgrade include a LVZPF price target?

No. The Goldman Sachs note did not publish a **LVZPF price target** and the release showed Price at Time as **N/A** and **0.0% ($0.0)** immediate movement.

How should investors use the LVZPF analyst rating change?

Use the LVZPF analyst rating change as one data point. Reassess position sizing, monitor upcoming earnings and regulatory news, and compare other analyst views before making medium or long-term moves.

What is Meyka AI's view of LVZPF after the downgrade?

Meyka AI rates LVZPF **B+**, noting the Goldman Sachs downgrade as notable but not dispositive. Our grade weighs benchmarks, sector trends, financial growth, and analyst consensus.

Analyst Ratings

Goldman Sachs Downgrades LVZPF Livzon Pharmaceutical to Sell Feb 2026

ByDanny Kontos February 6, 2026February 6, 2026

Goldman Sachs downgraded LVZPF (Livzon Pharmaceutical Group Inc.) to Sell on February 05, 2026 at 11:14 AM, marking the most significant analyst move for the name this month. The LVZPF analyst rating change from a Neutral to Sell signals heightened concern from a major wall‑street desk. No price target was published and the report noted no immediate price movement at post. This downgrade may alter sentiment for holders and prospective buyers of LVZPF given Goldman Sachs’ influence among institutional investors.